Vegetable-based drug could inhibit melanoma

March 1, 2009

Compounds extracted from green vegetables such as broccoli and cabbage could be a potent drug against melanoma, according to cancer researchers. Tests on mice suggest that these compounds, when combined with selenium, target tumors more safely and effectively than conventional therapy.

"There are currently no drugs to target the proteins that trigger melanoma," said Gavin Robertson, associate professor of pharmacology, pathology and dermatology, Penn State College of Medicine. "We have developed drugs from naturally occurring compounds that can inhibit the growth of tumors in mice by 50 to 60 percent with a very low dose."

Robertson and his colleagues previously showed the therapeutic potential of targeting the Akt3 protein in inhibiting the development of melanoma. The search for a drug to block the protein led them to a class of compounds called isothiocyanates.

These naturally occurring chemicals found in cruciferous vegetables are known to have certain cancer-fighting properties. However, the potency of these compounds is so low that a successful drug would require large impractical amounts of these compounds.

Instead, the Penn State researchers rewired the compounds by replacing their sulfur bonds with selenium. The result, they believe, is a more potent drug that can be delivered intravenously in low doses.

"Selenium deficiency is common in cancer patients, including those diagnosed with metastatic melanoma," explained Robertson, whose findings appear in the March edition of Clinical Cancer Research. "Besides, selenium is known to destabilize Akt proteins in prostate cancer cells."

To study the effectiveness of the new drug -- isoselenocyanate -- researchers injected mice with 10 million cancer cells. Six days later, when the animals developed large tumors, they were divided into two groups and treated separately with either the vegetable compounds or the compounds supplemented with selenium.

"We found that the selenium-enhanced compounds significantly reduced the production of Akt3 protein and shut down its signaling network," explained Robertson, who is also associate director of translational research and leader of the experimental therapeutics program at Penn State Hershey Cancer Institute. The modified compounds also reduced the growth of tumors by 60 percent, compared to the vegetable-based compounds alone.

When the researchers exposed three different human melanoma cell lines to the two compounds, the selenium-enhanced drug worked better on some cell lines than others. The efficiency was from 30 to 70 percent depending on the cell line.

The exact mechanism of how selenium inhibits cancer remains unclear. However Robertson, who has a filed provisional patent on the discovery, is convinced that the use of naturally occurring compounds that target cancer-causing proteins could lead to more effective ways of treating melanoma.

"We have harnessed something found in nature to target melanoma," said Robertson. "And since we only need tiny amounts to kill the cancer cells, it means even less toxic side-effects for the patient."

Human trials of the new drug are still some years away, but the Penn State researcher envisions a drug that could be delivered either intravenously to treat melanoma, or added to sunscreen lotion to prevent the disease.

Source: Penn State

Explore further: To improve melanoma treatment, researchers look to block deletion of 'self-reactive' immune cells

Related Stories

To improve melanoma treatment, researchers look to block deletion of 'self-reactive' immune cells

September 28, 2017
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center are using what they know about a rare, inherited autoimmune disease to turn the body's defenses against melanoma.

Parkinson's disease drug shows anticancer effects

September 28, 2017
Research shows the Parkinson's disease drug carbidopa displays significant anticancer effects in both human cell lines and mice when given at normal patient dosage levels.

Researchers identify new target, develop new drug for cancer therapies

September 20, 2017
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to ...

New system finds and targets vulnerabilities in lung cancer cells

October 2, 2017
Genetic changes that help lung cancer thrive also make it vulnerable to a promising experimental drug, according to a study led by researchers from Perlmutter Cancer at NYU Langone Health, and published online October 2 in ...

Light-based cancer therapy moves through clinical trials

September 27, 2017
In 2016, a dog named Eliza made the national news after a miraculous recovery from a terminal cancer diagnosis. The 13-year-old Labrador retriever had been given five weeks to live when she received "immunolight therapy," ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
1 / 5 (1) Mar 01, 2009
Some compounds RAISE cell temps., and some lower it. Needs vary in the same body.High temps. accelereate mitosis. Low temps DECELERATE it!
fixer
not rated yet Mar 01, 2009
why bother? If human tests are years away it's already out of date.
Au-Pu
not rated yet Mar 02, 2009
According to a local news report last year, The Royal Prince Alfred Hospital in Sydney Australia ran tests in 2008 where a substance called "Madras Pink" was injected directly into melanomas killing the melanoma within 48 hours.
I have heard nothing more of this experiment since.
It appears that the patients used in this experiment were all advanced melanoma cases.
This could be worth following up.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.